Why phesi
Phesi has been at the table with life sciences companies guiding clinical development since our inception in 2007.
INNOVATIVE
We build clinical development solutions using patented statistical models and advanced technologies such as big data, nature language processing, and machine learning.
FLEXIBLE
We provide fully customized services to clinical trial sponsors or CROs of any size, and ensure easy integration with their existing solutions.
COMPREHENSIVE
Our massive database provides insights to clinical studies of all phases across all therapeutic areas from all countries and geographical regions.
EFFECTIVE
Proven by hundreds of clinical studies, our solutions help our clients improve clinical operation productivity, saving them a huge amount of time and money.
CLIENT Testimonials
Phesi worked with us to show that a particular adaptive trial design would give the best performance. The result was a significantly quicker and cheaper development time on this priority asset.
Phesi is on the frontiers of defining clinical development as a science, performing systematic analysis of the clinical trial, clinical protocol, and clinical site space to form hypotheses about what will work and what will not. Through observation and experiment you are applying those learnings to inform new clinical programs or save old ones. Phesi is more than the sum of its parts and the value is in the integration.
Every global R&D leader should know about this and should be testing it within their portfolio.
LATEST NEWS
EAST LYME, Conn. Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite™ license to enable more accurate and precise planning for Phase 2 and 3 clinical trials of anticancer immunotherapies developed with OncoSec’s plasmid DNA delivery platform. ClinSite is a self-service, artificial intelligence (AI)-powered…
EAST LYME, Conn. Phesi is delighted to announce the appointment of Dan Manak to the role of Executive Director for Business Development. Dan is based in the US and has been working in pharma and clinical research for over 20 years, selling advanced clinical data analytics and AI technology and services to sponsor companies, enabling site selection and site management. On…
Journalist Dick Anderson conducted an interview with Dr. Gen Li, founder and president of Phesi. Gen Li was an instructor of neuroscience at Weill Cornell Medicine in 1996 when he enrolled in the inaugural class of Johnson’s One-Year MBA program for students with advanced technology degrees. He recalls a team-building session when a peer said, “Gen, you have an amazing capability in seeing…